@article{TLCR29661,
author = {Zimu Wang and Ping Zhan and Yanling Lv and Kaikai Shen and Yuqing Wei and Hongbing Liu and Yong Song},
title = {Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {3},
year = {2019},
keywords = {},
abstract = {Background: Neutrophil-to-lymphocyte ratio (NLR) is related to prognosis in non-small cell lung cancer (NSCLC). However, no consensus on the relationship of pretreatment NLR and survival outcomes of systemic therapy in NSCLC exists. This meta-analysis investigated the prognostic role of pretreatment NLR during systemic therapy for NSCLC, including chemotherapy, immunotherapy and targeted therapy.
Methods: PubMed, Web of Science and Cochrane Library databases were systematically searched up to April 09, 2019. Hazard ratios (HRs) with their 95% confidence intervals (CIs) were pooled to investigate the association of pretreatment NLR with progression-free survival (PFS) and overall survival (OS).
Results: In total, 27 articles with 4,298 participants were selected. The pooled results showed that elevated pretreatment NLR was associated with inferior PFS (HR, 1.45, 95% CI, 1.28–1.66) and OS (HR, 1.63, 95% CI, 1.43–1.84) during systemic therapy. Subgroup analyses according to the treatment strategy suggested that higher pretreatment NLR was significantly associated with shorter survival in all therapies, including chemotherapy (PFS HR, 1.74, 95% CI, 1.39–2.17; OS HR, 1.73, 95% CI, 1.26–2.36), immunotherapy (PFS HR, 1.53, 95% CI, 1.27–1.84; OS HR, 2.50, 95% CI, 1.60–3.89) and targeted therapy (PFS HR, 1.53, 95% CI, 1.04–2.25; OS HR, 1.92, 95% CI, 1.14–3.24).
Conclusions: Pretreatment NLR is a promising prognostic indicator for NSCLC patients receiving systemic therapy, including chemotherapy, immunotherapy and targeted therapy.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/29661}
}